Liên Minh Châu Âu - Tiếng Anh - EMA (European Medicines Agency)

clinuvel europe limited - afamelanotide - protoporphyria, erythropoietic - emollients and protectives - prevention of phototoxicity in adult patients with erythropoietic protoporphyria (epp).

Liên Minh Châu Âu - Tiếng Anh - EMA (European Medicines Agency)

pfizer europe ma eeig - voriconazole - candidiasis; mycoses; aspergillosis - antimycotics for systemic use - voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of in candidaemianon-neutropenic patients;treatment of fluconazole-resistant serious invasive candida infections (including c. krusei);treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.vfend should be administered primarily to patients with progressive, possibly life-threatening infections.prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - voriconazole 200mg - film coated tablet - 200 mg - active: voriconazole 200mg excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate maize starch opadry white 33k18618 povidone pregelatinised maize starch - voriconazole is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - voriconazole 50mg - film coated tablet - 50 mg - active: voriconazole 50mg excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate maize starch opadry white 33k18618 povidone pregelatinised maize starch - voriconazole is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

neo health (nz) limited - voriconazole 200mg - powder for injection - 200 mg - active: voriconazole 200mg excipient: hydrochloric acid hydroxypropyl-beta-cyclodextrin sodium chloride water for injection - voriconazole is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

viatris limited - voriconazole 200mg;  ;   - film coated tablet - 200 mg - active: voriconazole 200mg     excipient: croscarmellose sodium lactose monohydrate magnesium stearate opadry white povidone pregelatinised maize starch - vttack is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

viatris limited - voriconazole 50mg;  ;   - film coated tablet - 50 mg - active: voriconazole 50mg     excipient: croscarmellose sodium lactose monohydrate magnesium stearate opadry white 31k58902 povidone pregelatinised maize starch - vttack is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - voriconazole -

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: sodium chloride; hydroxypropylbetadex - voriconazole wockhardt is indicated for treatment of the following fungal infections:,invasive aspergillosis.,serious candida infections (including c. krusei), including systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,serious fungal infections caused by scedosporium spp and fusarium spp.,other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: sodium chloride; hydroxypropylbetadex - voriwok is indicated for treatment of the following fungal infections:,invasive aspergillosis.,serious candida infections (including c. krusei), including systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,serious fungal infections caused by scedosporium spp and fusarium spp.,other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.